Genetic polymorphisms associated with risk of venous thromboembolism in multiple myeloma patients treated with thalidomide.

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ALMÁŠI Martina ŠEVČÍKOVÁ Sabina SLABÝ Ondřej ŠVÁCHOVÁ Hana POUR Luděk KAISAROVA Petra HÁJEK Roman
Year of publication	2011
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Venous thromboembolism (VTE) is a common side-effect of thalidomide treatment in patients with multiple myeloma (MM). In our retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNPs) - CINP (rs7011), CETP (rs289747), ALDH1A1 (rs610529), CDKN1A (rs3829963), GAN (rs2608555), VEGF (rs699947) and ALDH1A1 (rs168351). Further studies are needed to confirm the initial analysis that provided predictive information of genetic variations in myeloma patients that may influence risk of VTE.
Related projects:	University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies